StockData
Bright Minds Biosciences Inc. logo

Bright Minds Biosciences Inc. (DRUG) stock

DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 23, 2025Score 5/30
$20.76+0.25 (+1.22%)

Close on Nov 18, 2026Market cap $158.52MP/E –Yield –

Bright Minds Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was C$11.08M, up 839.4% from the year before. The highest annual figure on record is C$12.18M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025C$11.08M+839.4%
FY2024Sep 30, 2024C$1.18M-76.4%
FY2023Sep 30, 2023C$5.00M-59.0%
FY2022Sep 30, 2022C$12.18M+92.9%
FY2021Sep 30, 2021C$6.31M+1679.3%
FY2020Sep 30, 2020C$354.85K–

More Bright Minds Biosciences figures

See a number that looks wrong?